ALVIOValerio Therapeutics Société anonymeALVIO info
$0.09info1.40%24h
Global rank31671
Market cap$13.65M
Change 7d-
YTD Performance-50.80%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Valerio Therapeutics Société anonyme (ALVIO) Stock Overview

    Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for treating DNA damage response and immuno-oncology; and platON, a decoy oligonucleotide platform. It has a license agreement with Acrotech Biopharma LLC; and clinical research agreement with Gustave Roussy to conduct clinical trial of AsiDNA for the treatment of relapsed ovarian cancer. The company was formerly known as Onxeo SA and changed its name to Valerio Therapeutics Société anonyme in June 2023. Valerio Therapeutics Société anonyme was incorporated in 1997 and is headquartered in Paris, France.

    ALVIO Stock Information

    Symbol
    ALVIO
    Address
    49, Bd du Général Martial ValinParis, 75015France
    Founded
    -
    Trading hours
    -
    Website
    https://valeriotx.com
    Country
    🇫🇷 France
    Phone Number
    33 1 45 58 76 00

    Valerio Therapeutics Société anonyme (ALVIO) Price Chart

    -
    Value:-

    Valerio Therapeutics Société anonyme Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $0.08858508391686117
    N/A
    Market Cap
    $13.65M
    N/A
    Shares Outstanding
    154.08M
    N/A
    Employees
    39.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    © 2024 Topstocks.org